Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

3(42.9%)

N/A

3(42.9%)

Phase 3

1(14.3%)

7Total

Phase 2(3)

N/A(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07207057Phase 3Recruiting

Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial

Role: collaborator

NCT07038603Not ApplicableCompleted

Feasibility of a Behavioural Activation Protocol to Support People With Parkinson's Enhanced by VR

Role: collaborator

NCT06193252Not ApplicableRecruiting

Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-Netherlands

Role: collaborator

NCT06993142Not ApplicableNot Yet Recruiting

Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage

Role: collaborator

NCT02881099Completed

Parkinson's Repository of Biosamples and Network Datasets (Tracking Parkinson's)

Role: collaborator

NCT05148884Phase 2Completed

Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia

Role: collaborator

NCT04167813Phase 2Active Not Recruiting

Trial of Ondansetron as a Parkinson's HAllucinations Treatment

Role: collaborator

NCT04810104Phase 2Withdrawn

Parkinson's Disease With Mild Cognitive Impairment Treated With Nicotinic Agonist Drug

Role: collaborator

NCT02760108Recruiting

Parkinson's Families Project

Role: collaborator

All 9 trials loaded